Prostate cancer: Information for black men

• Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. 2013 May;63(5):800–9.
• Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. The Risk of Prostate Cancer amongst Black Men in the United Kingdom: The PROCESS Cohort Study. Eur Urol. 2008 Jan;53(1):99–105.
• Cancer Research UK. Prostate cancer incidence statistics: Prostate cancer incidence by age (2011-2013) [Internet]. [cited 2016 Jun 9]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence
• Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res (Phila Pa). 2011 Jan 13;4(4):486–501.
• Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008 Jun 6;0(0):080606123516618
• Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Jan 6;23(7):1665–71.
• Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer: Metabolic Factors and Prostate Cancer. Cancer. 2012 Dec 15;118(24):6199–206.
• Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, et al. Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. Eur Urol. 2012 Nov;62(5):910–6.
• Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med [Internet]. 2015 Dec [cited 2015 Nov 5];13(1). Available from: http://www.biomedcentral.com/1741-7015/13/171
• Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M, et al. Guidelines on prostate cancer. European Association of Urology; 2016.
• National Institute for Clinical Excellence. Clinical Knowledge Summary: prostate cancer diagnosis [Internet]. 2011 [cited 2016 Oct 12]. Available from: http://cks.nice.org.uk/prostate-cancer#!diagnosis
• National Institute for Clinical Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
• National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE Guideline 12. June 2015 [Internet]. 2015. Available from: http://www.nice.org.uk/guidance/ng12/evidence/full-guidance-65700685
• Opinium Research for Prostate Cancer UK. Figures from Opinium Research LLP. Total sample size was 3647 UK adults, of which 212 were Black men. Fieldwork was undertaken between 15th February and 6th March 2016. The survey was carried out online. The figures have been weighted and are representative of all UK adults (aged 18+). 2016.
• Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, et al. Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up. Eur Urol. 2013;63(3):428–35.
• Public Health England. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing [Internet]. GOV.UK; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing
• World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf
  
  

Updated: November 2016 | Due for Review: November 2018